A randomised controlled trial to assess the effectiveness and cost of a patient orientated self management approach to chronic inflammatory bowel disease

Kennedy, A. P.; Nelson, E.; Reeves, D.; Richardson, G.; Roberts, C.; Robinson, A.; Rogers, A. E.; Sculpher, M.; Thompson, D. G.
November 2004
Gut;Nov2004, Vol. 53 Issue 11, p1639
Academic Journal
Objectives: We developed a patient centred approach to chronic disease self management by providing information designed to promote patient choice. We then conducted a randomised controlled trial of the approach in inflammatory bowel disease (IBD) to assess whether it could alter clinical outcome and affect health service use. Design: A multicentre cluster randomised controlled trial. Setting: The trial was conducted in the outpatient departments of 19 hospitals with randomisation by treatment centre, 10 control sites, and nine intervention sites. For patients at intervention sites, an individual self management plan was negotiated and written information provided. Participants: A total of 700 patients with established inflammatory bowel disease were recruited. Main outcome measures: Main outcome measures recorded at one year were: quality of life, health service resource use, and patient satisfaction. Secondary outcomes included measures of enablement-confidence to cope with the condition. Results: One year following the intervention, self managing patients had made fewer hospital visits (difference —1.04 (95% confidence interval (CI) —1.43 to —0.65); p<0.001) without increase in the number of primary care visits, and quality of life was maintained without evidence of anxiety about the programme. The two groups were similar with respect to satisfaction with consultations. Immediately after the initial consultation, those who had undergone self management training reported greater confidence in being able to cope with their condition (difference 0.90 (95% CI 0.12–1.68); p<0.03). Conclusions: Adoption of this approach for the management of chronic disease such as IBD in the NHS and other managed health care organisations would considerably reduce health provision costs and benefit disease control.


Related Articles

  • Challenges and strategies of children and adolescents with inflammatory bowel disease: a qualitative examination. Nicholas, David B.; Otley, Anthony; Smith, Claire; Avolio, Julie; Munk, Marla; Griffiths, Anne M. // Health & Quality of Life Outcomes;2007, Vol. 5, p28 

    Background: The aims of this study were to understand the lived experience and elements of quality of life as depicted by children and adolescents with inflammatory bowel disease (IBD). Methods: Eighty participants with IBD, ranging in age from 7 to 19 years, were interviewed about the impact of...

  • Probiotics and inflammatory bowel diseases. Bai, A-P.; Ouyang, Q. // Postgraduate Medical Journal;Jun2006, Vol. 82 Issue 968, p376 

    Enteric microflora profiles vary considerably between active inflammatory bowel diseases (IBD) and healthy conditions. Intestinal microflora may partake in the pathogenesis of IBD by one or some ways: specific pathogenic infection induces abnormal intestinal mucosal inflammation; aberrant...

  • Curcumin for inflammatory bowel disease. Gaby, Alan R. // Townsend Letter;Feb/Mar2006, Issue 271/272, p30 

    The article offers information about the curcumin, a component of the common spice called turmeric. Animal studies demonstrated an anti-inflammatory effect of curcumin, an un uncontrolled trial in humans that might be beneficial in the treatment of rheumatoid arthritis. Curcumin may also be an...

  • Cross-Cultural Variation in Disease-Related Concerns Among Patients With Inflammatory Bowel Disease. Levenstein, Susan; Zhiming Li; Almer, Sven; Barbosa, Antonio; Marquis, Patrick; Moser, Gabriele; Sperber, Ami; Toner, Brenda; Drossman, Douglas A. // American Journal of Gastroenterology;Jun2001, Vol. 96 Issue 6, p1822 

    OBJECTIVE: The aim of this work was to study cross-cultural variations in the impact of inflammatory bowel disease (IBD) on health-related quality of life by an international comparison of disease-related concerns. METHODS: Item and factor scores on the Rating Form of Inflammatory Bowel Disease...

  • Open access cots IBD hospitalisation.  // Pulse;10/25/2004, Vol. 64 Issue 42, p15 

    Reports on a study which found that giving inflammatory bowel disease patients open access to a consultant reduces hospital visits but not general practitioner workload in Great Britain. Effect of open access to patients' confidence to cope, quality of life and level of anxiety.

  • Evaluation of the Quantum Blue® rapid test for faecal calprotectin. Wassell, Julie; Wallage, Michael; Brewer, Ella // Annals of Clinical Biochemistry;Jan2012, Vol. 49 Issue 1, p55 

    Background: Calprotectin is an acute-phase protein used extensively in the assessment of gastrointestinal inflammation. It can readily be measured by enzyme-linked immunoassay (ELISA) and recently by point-of-care testing (POCT). We evaluated the Quantum Blue® POCT in this study and compared...

  • 6-MERCAPTOPURINE FOR THE MANAGEMENT OF ULCERATIVE COLITIS: A CONCEPT WHOSE TIME HAS COME. Peppercorn, Mark A. // American Journal of Gastroenterology;Sep1996, Vol. 91 Issue 9, p1689 

    Comments on several researches concerning the role of 6-mercaptopurine (6-MP) in the management of ulcerative colitis. Benefits of 6-MP for patients of Crohn's disease; Reasons for the reluctance of patients in using 6-MP for the management of ulcerative colitis; Comparison of the risks...

  • Environmental risk factors in paediatric inflammatory bowel diseases: a population based case control study. Baron, S.; Turck, D.; Leplat, C.; Merle, V.; Gower-Rousseau, C.; Marti, R.; Yzet, T.; Lerebours, E.; Dupas, J-L.; Debeugny, S.; Solomez, J-L.; Cortot, A.; Colombel, J-F. // Gut;Mar2005, Vol. 54 Issue 3, p357 

    Background: Environmental exposures in early life have been implicated in the aetiology of inflammatory bowel disease. Objective: To examine environmental risk factors prior to the development of inflammatory bowel disease in a paediatric population based case control study. Methods: A total of...

  • Medication beliefs among patients with inflammatory bowel disease who report low quality of life: a qualitative study. Hall, Nicola J; Rubin, Gregory P; Hungin, APS; Dougall, Audrey // BMC Gastroenterology;2007, Vol. 7, p20 

    Background: Non-adherence to drug therapy is common in Inflammatory Bowel Disease (IBD). Patients' beliefs about treatment have an important influence on adherence. An in-depth understanding of this area is, therefore, important for patient-centred care. The aim of the study was to assess...


Read the Article


Sign out of this library

Other Topics